(Q42998840)

English

Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus

scientific article published on 22 July 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

0 references

liver transplantation

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

17

object named as

Hideki Ohdan

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Kazuaki Chayama

18

object named as

Kazuaki Chayama

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

13

object named as

Michio Imamura

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

15

object named as

Hiroshi Aikata

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

6

object named as

Masataka Tsuge

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Tomokazu Kawaoka

1

object named as

Tomokazu Kawaoka

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yoshiiku Kawakami

14

object named as

Yoshiiku Kawakami

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Akira Hiramatsu

11

object named as

Akira Hiramatsu

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Shoichi Takahashi

3

object named as

Shoichi Takahashi

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Nobuhiko Hiraga

2

object named as

Nobuhiko Hiraga

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

7

object named as

Yuko Nagaoki

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Shintaro Takaki

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Fukiko Mitsui

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yuki Kimura

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yoshimasa Hashimoto

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yoshio Katamura

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Koji Waki

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hirotaka Tashiro

16

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

22 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Scandinavian Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1488-1496

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

The association between hepatitis C infection and survival after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Preemptive therapy for hepatitis C virus after living-donor liver transplantation

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Living donor liver transplantation for patients with hepatitis C virus cirrhosis: Tokyo experience

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Treatment of acute hepatitis C with interferon alfa-2b

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2010.505657

21 January 2018

Identifiers

10.3109/00365521.2010.505657

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42998840&oldid=1976317723"